Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy

NCT05415410 is registered in ClinicalTrials.gov with VectivBio AG as lead sponsor.

NCT NCT05415410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05415410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-blind Trial to Evaluate the Safety and Efficacy of Apraglutide in Subjects With Grade II to IV (MAGIC) Steroid Refractory Gastrointestinal (GI) Acute Graft Versus Host Disease on Best Available Therapy
Lead sponsor
VectivBio AG
Phase
Phase 2
Overall status
Terminated
Start date
May 25, 2022
Completion date
December 17, 2024
Enrollment
31 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gvhd